Leonard Gomella, MD

Articles

Dr. Gomella on the Challenges of Optimizing PSA as a Biomarker in Prostate Cancer

January 13th 2022

Leonard G. Gomella, MD, discusses the challenges of optimizing prostate-specific antigen as a biomarker in prostate cancer.

Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC

July 13th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

Dr. Gomella on Screening in Prostate Cancer

March 22nd 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, encourages early screening for prostate cancer.

Dr. Gomella on Immunotherapy Developments in Prostate Cancer

March 19th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy developments for patients with prostate cancer.

Dr. Gomella Discusses Precision Medicine in Prostate Cancer

March 9th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the role of precision medicine in prostate cancer.

Dr. Gomella on Enzalutamide in Prostate Cancer

February 27th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses enzalutamide (Xtandi) for patients with nonmetastatic castration-resistant prostate cancer.

Dr. Gomella on the FDA Approval of Apalutamide for Nonmetastatic CRPC

February 20th 2018

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Gomella on Ongoing Trials of Immunotherapy in Bladder Cancer

April 12th 2017

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses ongoing trials of immunotherapy for patients with bladder cancer.

Dr. Gomella Discusses Immunotherapy in Bladder Cancer

April 11th 2017

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

Dr. Gomella on Challenges Facing Genetic Testing in Prostate Cancer

March 10th 2017

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses challenges facing genetic testing for patients with prostate cancer.

Dr. Gomella Discusses New Data on Sipuleucel-T

January 31st 2014

Leonard Gomella, MD, from the Kimmel Cancer Center Network, Thomas Jefferson University Hospital, provides an update on the dendritic cell cancer vaccine sipuleucel-T in castration-resistant prostate cancer.